Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion
Authors:
- Lavinia RaimondiLRLavinia Raimondi
- Alessia GalloAGAlessia Gallo
- Nicola CuscinoNCNicola Cuscino
- Angela De LucaALAngela De Luca
- Viviana CostaVCViviana Costa
- Valeria CarinaVCValeria Carina
- Daniele BellaviaDaniele Bellavia
- Matteo BulatiMBMatteo Bulati
- Riccardo AlessandroRiccardo Alessandro
- Milena FiniMilena Fini
- Pier Giulio ConaldiPCPier Giulio Conaldi
- Gianluca GiavaresiGianluca Giavaresi
Open Access
- 9 January 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 705
Abstract
Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our knowledge on the fifth candidate renamed now miR-CT3. MiR-CT3 expression was low in OS cells when compared with human primary osteoblasts and healthy bone. Through TargetScan, VEGF-A was predicted as a potential biological target of miR-CT3 and luciferase assay confirmed it. We showed that enforced expression of miR-CT3 in two OS cell lines, SAOS-2 and MG-63, reduced expression of VEGF-A mRNA and protein, inhibiting tumor angiogenesis. Enforced expression of miR-CT3 also reduced OS cell migration and invasion as confirmed by soft agar colony formation assay. Interestingly, we found that miR-CT3 behaves inducing the activation of p38 MAP kinase pathway and modulating the epithelial-mesenchymal transition (EMT) proteins, in particular reducing Vimentin expression. Overall, our study highlights the novel role of miR-CT3 in regulating tumor angiogenesis and progression in OS cells, linking also to the modulation of EMT proteins.Keywords
Funding Information
- Italian Ministry of Health (Fondi 5 per mille ANNO 2019 redditi 2018 - Il microambiente tumorale come bersaglio per terapie innovative nei tumori muscoloscheletrici)
This publication has 67 references indexed in Scilit:
- PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant TransformationPLOS Genetics, 2013
- Snail2 promotes osteosarcoma cell motility through remodelling of the actin cytoskeleton and regulates tumor developmentCancer Letters, 2013
- Osteosarcoma: Evolution of Treatment ParadigmsSarcoma, 2013
- Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cellsOncology Reports, 2013
- miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cellsInternational Journal of Molecular Medicine, 2012
- MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future DirectionsSarcoma, 2012
- MicroRNA Involvement in OsteosarcomaSarcoma, 2012
- High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern ChinaWorld Journal of Surgical Oncology, 2012
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcomaCancer, 2011
- Osteosarcomagenesis: Modeling Cancer Initiation in the MouseSarcoma, 2011